Close

Industry Reports

Lilly To Provide Detailed Update Of Pipeline And R&D...

Eli Lilly and Company announced it will host a meeting for the investment community, including institutional investors, sell-side analysts, ratings agency representatives, and financial and...

INNATE PHARMA IN-LICENSES OREGA BIOTECH’S FIRST-IN-CLASS ANTI-CD39 CHECKPOINT INHIBITOR...

This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses...

CTI BioPharma Announces $15.7 Million Registered Direct Offering

CTI BioPharma Corp. announced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company's common stock in...

Seattle Genetics, BMS to evaluate Adcetris and Opdivo combination

Seattle Genetics and Bristol-Myers Squibb (BMS) have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Adcetris and Opdivo in two...

Ireland’s Shire to acquire NPS Pharmaceuticals for $5.2bn

Irish drugmaker Shire has signed a merger agreement to acquire US-based NPS Pharmaceuticals for $5.2bn. As part of the deal, Shire will...

Pfizer acquires Baxter’s marketed vaccines portfolio for $635m

US-based drug maker Pfizer has completed the acquisition of marketed vaccines portfolio from Baxter International for $635m. As part of the deal,...

Johnson & Johnson completes acquisition of AliosBioPharma for $1.75bn

US-based Johnson & Johnson (J&J) has completed the acquisition of a privately held clinical stage biopharmaceutical company, AliosBioPharma, for $1.75bn in cash. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read